Alicia Romano
Pediatric Endocrinology · Sleepy Hollow, NYNPI 1487646063
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 69.3% of it on its own, with 16 other manufacturers making up the rest. Among pediatric endocrinology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $1026.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$109K
- Novo Nordisk Health Care AG$40K
- Biomarin Pharmaceutical Inc.$7K
- Eton Pharmaceuticals, Inc.$176
- Insulet Corporation$171
- AbbVie$110
- plus $403 from 11 others
What the payments were for
- Consulting fees$42,29027%
- Speaking & faculty fees$85,05854%
- Travel & lodging$26,38317%
- Food & beverage$3,2732%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 95 | $108,821 |
| Novo Nordisk Health Care AG | 18 | $39,971 |
| Biomarin Pharmaceutical Inc. | 9 | $7,383 |
| Eton Pharmaceuticals, Inc. | 1 | $176 |
| Insulet Corporation | 7 | $171 |
| AbbVie | 6 | $110 |
| Cumberland Pharmaceuticals, Inc. | 1 | $71 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Pfizer | 3 | $50 |
| Abbott | 2 | $47 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$78,862
- Sogroya$65,001
- VOXZOGO 1.2mg$7,190
- Saxenda$2,380
- Alkindi$176
How this compares
$157,036 in reported general payments places this provider in the 95th percentile of 138 pediatric endocrinology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $4812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pediatric endocrinology providers in New York.
Other pediatric endocrinology in Sleepy Hollow
- Vardhini DesikanSleepy Hollow$5K
- Mary DamoreSleepy Hollow$4K
- Richard NotoSleepy Hollow$4K
- Paul SaengerMineola$180K
- Svetlana TenStaten Island$101K
- Robert RapaportNew York$98K
- Moris AnguloMineola$73K
- Jill BrodskyPoughkeepsie$45K
- Jorge Mejia-CorlettoNorth Babylon$44K
- Angela VerardoBronx$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.